Entera Bio Ltd.
Entera Bio Ltd.
Your view on ENTX
Overview
What the company does, where it operates, and who runs it.
About Entera Bio Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Miranda J. Toledano
- Headquarters
- Kiryat Hadassah Minrav Building, Jerusalem, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Miranda J. Toledano
- Headquarters
- Kiryat Hadassah Minrav Building, Jerusalem, IL
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.
The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.
The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Entera Bio Ltd., and the rating behind it. ENTX last traded at $2.84; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Entera Bio Ltd.. Starting points for Entera Bio Ltd.: EPS -$0.34, beta 1.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Entera Bio Ltd.. Entera Bio Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Entera Bio Ltd.. Trailing twelve-month EPS for Entera Bio Ltd. stands at -$0.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Entera Bio Ltd.. Entera Bio Ltd. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Entera Bio Ltd. valued side by side against its closest peers. Entera Bio Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Entera Bio Ltd., and how their positions are changing. At a $140.0M market value, institutional positions materially move Entera Bio Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Entera Bio Ltd. executives and directors. Shares of Entera Bio Ltd. have traded between $1.50 and $3.22 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Entera Bio Ltd.. Entera Bio Ltd. is a $140.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Entera Bio Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Entera Bio Ltd.. Coverage tracks Entera Bio Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.